Join our daily newsletter At The Bell to receive exclusive market insights
- Imagion Biosystems (IBX) has appointed Geoff Hollis as its new Chief Financial Officer (CFO)
- Geoff is replacing Brian Conn and will begin his new role on December 1
- Previously, Geoff has been a CFO for multiple ASX listed companies, such as Lifestyle Communities (LIC)
- This appointment supports the next phase of growth for the company as it aims to develop and commercialise its medical device technology to non-invasively detect cancer
- On the market today, Imagion is up 2.6 per cent and is trading for 7.9 cents per share
Imagion Biosystems (IBX) has appointed Geoff Hollis as its new Chief Financial Officer (CFO).
This appointment supports the next phase of growth for the company as it aims to develop and commercialise its medical device technology to non-invasively detect cancer.
Geoff has been a CFO for multiple ASX listed companies, such as Lifestyle Communities (LIC), where he played a key role in cash management and financing to facilitate the company’s move to the ASX 300.
He will begin his new role at Imagion on December 1, 2020.
IBX CEO, Bob Proulx, is pleased to have Geoff join the team.
“Being based in Australia, Geoff will be well-positioned to assist with the
company’s developing business interests in Australia and will be closer to the company’s investors and the capital markets to facilitate investor relations,” he said.
“We look forward to having Geoff aboard as the Company moves through its next growth phase and as we plan to advance the business beyond our upcoming MagSense HER2 phase one study for metastatic breast cancer,” he added.
Geoff replaces Brian Conn, who has been part of the Imagion team as a part-time CFO since 2017. He left Imagion in August to take a full-time CFO position.
On the market today, Imagion is up 2.6 per cent and is trading for 7.9 cents per share at 12:25 am AEDT.
